EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSONIG00000012700
Gene Symbol: PIK3R2
1 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSONIG00000007853
Gene Symbol: PIK3R3
4 Cross references
171 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSONIG00000018156
Gene Symbol: PIK3R5
4 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3a (Gamma)

Ensembl ID : ENSONIG00000018604
Gene Symbol: PIK3R3A
1 Cross references
206 Possible Orthologues:

Phospholipase A2

Ensembl ID : ENSONIG00000035981
Gene Symbol: LOC100698203
4 Cross references
232 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSONIG00000001212
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSONIG00000001876
Gene Symbol: GART
4 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSONIG00000037127
Gene Symbol: PLG
1 Cross references
245 Possible Orthologues:

Plasminogen

Ensembl ID : ENSONIG00000029839
Gene Symbol: LOC100702940
3 Cross references
245 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSONIG00000014359
Gene Symbol: PLAT
4 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSONIG00000021381
Gene Symbol: PTAFR
3 Cross references
212 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSONIG00000004906
Gene Symbol: PTAFR
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).